Cytokines: Abnormalities in major depression and implications for pharmacological treatment

Human Psychopharmacology

Volumn 19, Issue 6, 2004, Pages 397-403

  O'Brien, Sinead M ^a   Scott, Lucinda V ^a   Dinan, Timothy G ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

Antidepressants; Cytokines; Depression; HPA axis; Interleukins; Psychoneuroimmunology

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CYTOKINE; DESIPRAMINE; FENCLONINE; FLESINOXAN; GAMMA INTERFERON; HYDROCORTISONE; IMIPRAMINE; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; RITANSERIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VENLAFAXINE;

CLINICAL STUDY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ILLNESS BEHAVIOR; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; MAJOR DEPRESSION; MEDLINE; MENTAL STRESS; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYMPTOMATOLOGY; TREATMENT PLANNING;

ANTIDEPRESSIVE AGENTS; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; HUMANS; IMMUNE SYSTEM; NEUROSECRETORY SYSTEMS; SEROTONIN; STRESS;

EID: 4444256765     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.609     Document Type: Review

References (73)

1. Ackerman KD, Martino M, Heyman R, Moyna NM, Rabin BS. 1996. Immunological response to acute physiological stress in MS patients and controls. J Neuroimmunol 68: 85-94.
2. Asberg M. 1997. Neurotransmitters and suicidal behaviour: the evidence from cerebrospinal fluid studies. Ann N Y Acad Sci 836: 18-81.
3. Benschop RJ, Godaert GL, Geenen R, et al. 1995. Relationships between cardiovascular and immunological changes in an experimental stress model. Psychol Med 25: 323-327.
4. Btatteis CM. 1990. Neuromodulative actions of cytokines. Yale J Biol Med 63: 133-146.
5. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. 1993. Glucocorticoid therapy for immune mediated diseases: basic and clinical correlates. Ann Intern Med 119: 1198-1208.
6. Brattsand R, Linden M. 1996. Cytokine modulation by glucocortocoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 10(Suppl. 2): 81-90.
7. Brown KA. 2001. Factors modifying the migration of lymphocytes across the blood-brain-barrier. Int Immunopharmacol 1: 2043-2062.
8. Chapman LF, Goodell H. 1963. The participation of the nervous system in the inflammatory reaction. Ann N Y Acad Sci 116: 990-1017.
9. Chrousos GP. 1995. The hypothalamic-pituitary-adrenal axis and immune mediated inflammation. N Engl J Med 332: 1351-1362.
10. Connor TJ, Kelly JP, Leonard BE. 2000. Olfactory bulbectomy provokes a suppression of interleukin-1 beta and tumour necrosis factor alpha production in response to an in vivo challenge with lipopolysaccharide: effect of chronic desimpramine treatment. Neuroimmunomodulation 7: 27-35.
11. Connor TJ, Leonard BE. 1998. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 62: 583-606.
12. Cooney JM, Dinan TG. 1996. Type 2 (glucocorticoid) receptors mediate fast feedback inhibition of the hypothalamic-pituitary-adrenal axis in man. Life Sci 59: 1981-1988.
13. Decker D, Schondorf M, Bidlingmater F, Hirner A, Von Rueker AA. 1996. Surgical stress induces a shift in the type 1/type 2 T-helper cell balance suggesting down regulation of cell mediated and up regulation of antibody mediated immunity commensurate to the trauma. Surgery 119: 316-325.
14. Delahanty DL, Wang T, Maravich C, Forlenza M, Baum A. 2000. Time of day effects on response of natural killer cells to acute stress in men and women. Health Psychol 19: 39-45.
15. Dentino AN, Pieper CF, Rao KMK, et al. 1999. Association of interleukin-6 and other biological variables with depression in older people living in the community. J Am Geriatr Soc 47: 6-11.
16. Dinan TG. 1994. Glucocorticoids and genesis of depressive illness: a psychological approach. Br J Psychiatry 164: 365-371.
17. Duman RS, Nestler EJ. 1995. Signal transduction pathways for catecholamine receptors. In Psychopharmacology: The Fourth Generation of Progress, Bloom FE, Kupfer DJ (eds). Raven: New York.
18. Dunn AJ. 1988. Systemic interleukin-1 administration stimulates hypothalamic norepinephrine metabolism paralleling the increased plasma corticosterone. Life Sci 43: 429-435.
19. Flanigan MJ, Accone Q, Laburn HP. 1992. Amitriptyline attenuates the febrile response to a pyrogen in rabbits. J Basic Clin Physiol Pharmacol 3: 19-32.
20. Green AI, Mooney JJ, Poesner JA, Schildkraut JJ. 1995. Mood disorders: biochemical aspects. In Comprehensive Textbook of Psychiatry/VI, Kaplan HI, Sadock BJ (eds). Williams and Wilkins: Baltimore; 1089-1102.
21. Henninger GR. 1995. The role of serotonin in clinical disorders. In Psychopharmacology: The Fourth Generation of Progress, Bloom FE, Kupfer DJ (eds). Raven: New York; 471-482.
22. Herbert TB, Cohen S. 1993. Stress and immunity in humans: a meta-analytic review. Psychosom Med 55: 364-379.
23. Herbert TB, Cohen S, Marsland AL, et al. 1994. Cardiovascular reactivity and the course of immune response to an acute psychological stressor. Psychosom Med 56: 337-344.
24. Heyes MP, Crowley JS, Davis LE, et al. 1992. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115: 1249-1273.
25. Hirano T, Akira S, Taga T, Kisimoto T. 1990. Biological and clinical aspects of interleukin-6. Immunol Today 11: 443-449.
26. Kabiersch A, del Rey A, Honegger CG, Besedovsky HO. 1998. Interleukin-1 induces changes in norepinephrine metabolism in the rat brain. Brain Behav Immunol 2: 267-274.
27. Kenis G, Maes M. 2002. Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol 5: 401-412.
28. Kiecolt-Glaser JK, Glaser R. 2002. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res 53: 873-876.
29. Kiecolt-Glaser JK, Malarky WB, Chec M, et al. 1993. Negative behaviour during marital conflict is associated with immunological down regulation. Psychosom Med 55: 395-409.
30. Klokker M, Secher NH, Madsen P, Pederson M, Pederson BK. 1997. Adrenergic beta 1- and beta 1+2 receptor blockade suppress the natural killer cell responses to head up tilt in humans. J Appl Physiol 83: 1492-1498.
31. Kubera M, Kenis G, Bosmans E, Scharpe S, Maes M. 2000. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. Neuropsychopharmacology 23: 89-98.
32. Kubera M, Lin AH, Kenis G, Bosmans E, Van Bockstaele D, Maes M. 2001. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 21: 199-206.
33. Kushner I. 1982. The phenomena of the acute phase response. Ann N Y Sci 389: 39-48.
34. Leonard BE. 2001. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 25: 767-780.
35. Levine J, Barak Y, Chengappa KN, Rappoport A, Rebey M, Barak V. 1999. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40: 171-176.
36. Maes M. 1997. The immune pathophysiology of major depression. In depression: Neurobiological, psychopathological and therapeutics advances. Honig A and Van Praag H (eds). John Wiley: Chichester; 197-215.
37. Maes M. 1999. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461: 25-46.
38. Maes M. 2001. The immunoregulatory effect of antidepressants. Hum Psychopharmacol Clin Exp 16: 95-103.
39. Maes M, Meltzer HY. 1995. The serotonin hypothesis of major depression. In Psychopharmacology: The Fourth Generation of Progress, Bloom FE, Kupfer DE (eds). Raven: New York; 933-944.
40. Mastorakos G, Chrousos GP, Weber JS. 1993. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 77: 1690-1694.
41. Mastorakos G, Weber JS, Magiakou GA, Gunn H, Chrousos GP. 1994. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 79: 934-939.
42. Mercado AM, Glaser R. 1995. Slowing of wound healing by psychological stress. Lancet 346: 1194-1196.
43. Mills PJ, Dimsdale JE, Nelesen RA, Dillon E. 1996. Psychological characteristics associated with acute stressor induced leucocyte subset redistribution. J Psychosom Res 40: 417-423.
44. Mills PJ, Heari SL, Dumsdale JE. 1995. Temporal stability of acute stressor-induced changes in cellular immunity. Int J Psychophysiol 19: 287-290.
45. Morikawa O, Sakai N, Obara H, Saito N. 1998. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349: 317-324.
46. Mossner R, Daniel S, Schmitt A, Albert D, Lesch KP. 2001. Modulation of serotonin transporter function by interleukin-4. Life Sci 68: 873-880.
47. Mossner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP. 1998. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int 33: 251-254.
48. O'Connor TM, O'Halloran DJ, Shanahan F. 2000. The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia. Q J Med 93: 323-333.
49. Papanicolaou DA, Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. 1998. The pathophysiology roles of interleukin 6 in human disease. Ann Int Med 128: 127-134.
50. Pawlak CR, Jacobs R, Mickeska E, et al. 1999. Patients with systemic lupus erythematosus differ from healthy controls in their immunological response to acute psychological stress. Brain Behav Immun 13: 287-302.
51. Paykel ES, Cooper Z. 1992. Life events and social stress. In Handbook of Affective Disorders, 2nd edn, Paykel ES (ed.). Churchill Livingston: London; 149-170.
52. Peters ML, Godaert GL, Ballieux RE, et al. 1999. Immune responses to experimental stress: effects of mental effort and uncontrollability. Psychosom Med 61: 513-524.
53. Ratson CL, Gummick JF, Miller AH. 2002. Neuroendocrine-immune interactions: implications for health and behaviour. In Hormones Brain and Behaviour, Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT (eds), Vol 5. Academic Press: New York; 209-262.
54. Rubin RT, Dinan TG, Scott LV. 2002. The neuroendocrinology of affective disorders. In Hormones Brain and Behaviour, Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT (eds), Vol. 5. Academic Press: New York; 467-514.
55. Schildkraut JJ, Orsulak PJ, Schatzberg AF, et al. 1978a. Towards a biochemical classification of depressive disorders 1: differences in urinary excretion of MPHG and other catecholamine metabolites in clinically defined subgroups of depressions. Arch Gen Psych 35: 1427-1433.
56. Schildkraut JJ, Orsulak PJ, LaBrie RA, et al. 1978b. Towards a biochemical classification of depressive disorders 11: application of mulfivariate discriminant function analysis to data on urinary catecholamines and metabolites. Arch Gen Psych 35: 1436-1439.
57. Scott LV, Dinan TG. 2002. Vasopressin as a target for antidepressant development: an analysis of the available evidence. J Affect Disord 72: 113-121.
58. Shen Y, Connor TJ, Nolan Y, Kelly JP, Leonard BE. 1999. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci 65: 1773-1786.
59. Smith RS. 1991. The macrophage theory of depression. Med Hypotheses 35: 298-306.
60. Song C, Dinan TG, Leonard BE. 1994. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord 30: 283-288.
61. Song C, Leonard BE. 1995. The effects of olfactory bulbectomy in the rat, alone and in combination with antidepressants and endogenous factors, on immune function. Hum Psychopharmacol 10: 7-18.
62. Sgoutas-Emch SA, Capcioppo JT, Uchino BN, et al. 1994. The effect of an acute psychological stressor on cardiovascular, endocrine, and cellular immune response: a prospective study of individuals high and low in heart rate reactivity. Psychophysiology 31: 264-409.
63. Stitt KA, Cowen PJ. 1997. Serotonin and depression. In Depression: Neurobiological, Psychopathological and Therapeutic Advances, Honig A, van Praag HM (eds). John Wiley and Sons: Chichester.
64. Thompson A. 1991. The Cytokine Handbook. Academic Press: London.
65. Thompson A. 1998. The Cytokine Handbook, 3rd edn. Academic Press: San Diego.
66. Turnbull AV, Rivier CL. 1999. Regulation of the hypothalamic-pituitary adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 79: 1-71.
67. van der Pompe G, Antoni MH, Visser A, Heijnen CJ. 1998. Effect of mild acute stress on immune cell distribution and natural killer cell activity in breast cancer patients. Biol Psychol 48: 21-35.
68. van Deventer SJH, Buller HR, ten Carte JW, Aarden LA, Hack CE, Sturk A. 1990. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76: 2520-2526.
69. Van Moffaert M, Dierick M. 1999. Noradrenaline (norepinephrine) and depression. CNS Drugs 12: 293-305.
70. Van Riezen H, Leonard BE. 1991. Effects of psychotrophic drugs on the behaviour and neurochemistry of olfactory bulbectomised rats. In Psychopharmacology of Anxiolytics and Antidepressants, File S (ed.). Pergamon: New York; 231-250.
71. Wichers M, Maes M. 2002. The psychoneuroimmuno-pathophysiology of cytokine induced depression in humans. Int J Neuropsychopharmacol 5: 375-388.
72. Xia Z, DePierre JW, Nassberger L. 1996. Tricyclic antidepressants inhibit IL-6, IL-1beta, and TNFalpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 34: 27-37.
73. Yirmiya R, Pollak Y, Morag M, et al. 2000. Illness, cytokines and depression. Ann N Y Acad Sci 917: 478-487.